Compare ADMA Biologics Inc (ADMA) vs Arko Corp. (ARKO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Arko Corp. — how do they compare? ADMA Biologics Inc trades at $9.22 (market cap $2.13B), while Arko Corp. trades at $8.06 (market cap $880.66M). The key difference: ADMA Biologics Inc is far larger — about 2.4× Arko Corp.'s market cap, and Arko Corp. pays a 1.53% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | ARKO | |
|---|---|---|
Market Cap | $2.13B | $880.66M |
Sector | Health | Consumer Cyclical |
52-Week High | $20.38 | $8.64 |
52-Week Low | $7.60 | $3.82 |
Enterprise Value | $2.20B | $3.05B |
Dividend Yield | — | 1.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
ARKO trades at $7.85, down 2.36% today, with a bullish technical signal from moving averages. The company reported Q1 2026 earnings of -$0.07 per share, beating expectations, but revenue has declined from $9.4B in 2023 to $7.6B in 2025. Net income margin remains thin at 0.38%, while the P/E ratio of 39.75 suggests high earnings expectations relative to current profits. Recent news highlights ARKO as a defensive pick amid inflation concerns.
The outlook is mixed: positive technical momentum and defensive stock characteristics offer upside, but weak revenue growth and low profitability pose risks. All covering analysts rate it Hold, indicating caution. Investment appeal hinges on margin improvement and stable cash flow to support dividends, though high debt and economic sensitivity remain concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Arko Corp.
ARKO Corp operates as a holding company. The company, through its subsidiaries, owns and operates convenience stores in the United States. Some of its regional store brands include Stop, Admiral, Apple Market, BreadBox, E-Z Mart, fas mart, Li'l Cricket, and Next Door Store. Its retail store offers hot food service, beverages, cigarettes & other tobacco products, candy, salty snacks, grocery, beer, and general merchandise. ARKO operates in three segments: Retail, Wholesale, and GPM Petroleum. The company derives the majority of its revenue from retail and wholesale distribution of fuel.
Read more on ARKO →
